There are 2789 resources available
758P - Concordance between multiple HRD assays is substantial in high-grade ovarian cancer
Presenter: Wilko Weichert
Session: ePoster Display
759P - Adding dosing of plasmid encoding p62/SQSTM1 to gemcitabine chemotherapy may provide clinical benefits to patients with platinum-resistant ovarian cancer
Presenter: Sergey Polyakov
Session: ePoster Display
760P - Straightforward molecular tests for predicting response and non-response to platinum-based neoadjuvant therapy in high-grade serous ovarian cancer patients
Presenter: Evgeny Imyanitov
Session: ePoster Display
761P - Impact of residual disease on outcomes in patients with ovarian cancer: A meta-analysis
Presenter: Dana Chase
Session: ePoster Display
762P - Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes
Presenter: Camilla Sköld
Session: ePoster Display
763P - Treatment response to non-platinum therapies in ovarian cancer patients according to BRCA status: A retrospective analysis of a large multicentric cohort
Presenter: Gaia Giannone
Session: ePoster Display
764P - Survey on the practical implementation of BRCA gene and HRD-testing and PARP-inhibitor management in Germany: A national NOGGO/JAGO-AGO intergroup study
Presenter: Joanna Baum
Session: ePoster Display
765P - Prognosis of BRCA1 and BRCA2 ovarian cancer: Prospective follow-up data from a multidisciplinary program
Presenter: Pedro Antunes Meireles
Session: ePoster Display
766P - Mapping BRCA1/2 variants in ovarian cancer patients: Contribution of a BRCA2 founder effect
Presenter: Teresa Duarte
Session: ePoster Display
767P - Retrospective analysis of the impact of bevacizumab dose-intensity on the survival of platinum-resistant ovarian cancer patients
Presenter: Jose Bahena
Session: ePoster Display